[1] |
中华医学会器官移植学分会. 器官移植术后乙型肝炎病毒感染诊疗规范(2019版)[J/CD]. 实用器官移植电子杂志, 2020, 8(2):81-85.
|
[2] |
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者肾损伤管理专家共识(2017版)[J]. 中华消化外科杂志, 2017, 16(4):319-326.
|
[3] |
李新宇,黄磊,朱继业, 等. 肝移植术后生存10年及以上患者远期并发症随访分析[J]. 中华全科医师杂志, 2019, 18(4):347-351.
|
[4] |
吕少诚,潘冰,李立新, 等. 不同肝癌肝移植标准受者预后分析[J/CD]. 中华移植杂志(电子版), 2019, 13(3):206-209.
|
[5] |
Umeshita K, Eguchi S, Egawa H, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society[J]. Hepatol Res, 2019, 49(9):964-980.
|
[6] |
王垒,范林,彭贵主, 等. 经胆囊管胆道引流在肝移植胆道并发症预防和治疗中的应用[J/CD]. 实用器官移植电子杂志, 2017, 5(1):52-55.
|
[7] |
中华医学会器官移植学分会. 中国肝移植术后并发症诊疗规范(2019版)[J]. 器官移植, 2021, 12(2):129-133.
|
[8] |
蔡云石,刘雄威,肖衡, 等. 肝移植术后胆道并发症的诊治[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(5):391-395.
|
[9] |
李名安,吴春,罗骏阳, 等. 经皮介入治疗在肝移植术后胆道并发症中的应用探讨[J]. 中华器官移植杂志, 2017, 38(3):165-171.
|
[10] |
蔡秋程,杨芳,张小进, 等. 肝移植5年后生存影响因素分析[J]. 肝胆外科杂志, 2013, 21(3):174-176.
|
[11] |
方程,严盛,郑树森. 肝移植术后胆道并发症的影响因素及诊治进展[J]. 中华普通外科杂志, 2014, 29(6):486-488.
|
[12] |
Fujiki M, Hashimoto K, Palaios E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients[J]. Surgery, 2017, 162(5):1101-1111.
|
[13] |
Dumortier J, Chambon-Augoyard C, Guillaud O, et al. Anastomotic bilio-biliary stricture after adult liver transplantation: a retrospective study over 20 years in a single center[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4):564-571.
|
[14] |
李彦杰,马毅,郭志勇, 等. 肝癌肝移植术后复发和转移特点及预后因素分析[J]. 中国实用外科杂志, 2012, 32(8):655-658.
|
[15] |
郑树森,程启阳,耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7):773-778.
|
[16] |
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5):857-862.
|
[17] |
陈凯,王唑,史政荣. 肝移植术后肿瘤复发与免疫抑制剂的关系[J]. 中华肝胆外科杂志,2021, 27(3):192-196.
|
[18] |
刘少儒,许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3):272-279.
|
[19] |
李照,朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2):249-252.
|
[20] |
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatology, 2017, 66(4):1036-1044.
|
[21] |
Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation[J]. Hepatol Res, 2013, 43(1):67-71.
|
[22] |
Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? systematic review and meta-analysis[J]. Transpl Infect Dis, 2010, 12(4):292-308.
|
[23] |
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020, 11(1):19-29.
|
[24] |
中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1):1-9.
|
[25] |
中华医学会器官移植学分会. 中国实体器官移植术后高血压诊疗规范(2019版)[J]. 器官移植, 2019, 10(2):112-121.
|
[26] |
Aibara N, Ohyama K, Hidaka M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018(48):60-64.
|
[27] |
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1):8-14, 28.
|
[28] |
Koo J, Wang HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452.
|